gdc-0449 has been researched along with Colonic-Neoplasms* in 2 studies
2 other study(ies) available for gdc-0449 and Colonic-Neoplasms
Article | Year |
---|---|
Hedgehog pathway inhibitors of the acylthiourea and acylguanidine class show antitumor activity on colon cancer in vitro and in vivo.
Small series of acylguanidine and acylthiourea derivatives were synthesized in gram-scale and assayed for their ability to modulate the Hh signalling pathway. In vitro studies showed a low micromolar inhibitory activity toward tumor cell lines, while the oral administration revealed an excellent ADME profile in vivo. Compound 5 emerged as the most active and safe inhibitor of colon cancer cells both in vitro and in a xenograft mouse model. Based on these data, 5 could be prioritized to further development with the perspective of clinical studies. Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Guanidine; Hedgehog Proteins; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; NIH 3T3 Cells; Structure-Activity Relationship; Thiourea | 2018 |
Discovery of a potent hedgehog pathway inhibitor capable of activating caspase8-dependent apoptosis.
Aberrant activation of Hedgehog (Hh) signaling is associated with the development of numerous human cancers. Vismodegib is the first Hh inhibitor approved for anti-cancer therapy by targeting Smoothened (SMO), a critical regulator of the Hh pathway. However, acquisition of drug resistance to vismodegib occurs overtime. Apoptosis is a prevalent form of programmed cell death that is executed by caspases. Induction of tumor cell apoptosis represents an attractive therapeutic strategy to eliminate tumor cells. To explore new Hh antagonists with apoptosis-inducing activity, we screened a set of ∼300 potential SMO antagonists with novel scaffold structures. Hh003 was found to induce caspase-dependent apoptosis while vismodegib did not activate apoptotic response in human colon and pancreatic cancer cells. Compared to vismodegib, Hh003 exerted similar inhibitory effects on the Hh pathway. Hh003 could induce caspase8 activation and the silence of caspase8 significantly inhibited Hh003-induced apoptosis. Remarkably, Hh003 showed stronger inhibitory effects on the formation of tumor colonies in vitro and colorectal tumor growth in vivo than vismodegib. These findings suggest that Hh003 exerts enhanced anti-tumor effects by activating caspase8-dependent apoptosis compared to vismodegib. The combined property of Hh inhibition and apoptosis induction of Hh003 presents great potential for the development of novel anti-cancer therapy. Topics: Anilides; Antineoplastic Agents; Apoptosis; Caspase 8; Colonic Neoplasms; Drug Discovery; Drug Screening Assays, Antitumor; HCT116 Cells; Hedgehog Proteins; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyridines; Signal Transduction | 2018 |